Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10604	Companies
225013	Keywords
153734	Articles
119075	Press releases

Home
Companies
Biophytis

BRIEF

published on 09/15/2025 at 07:05, 9 months 6 days ago

Biophytis Secures Funding for Obesity Trial in Brazil

Biophytis Brazil Obesity Trial EMBRAPII Clinical Partnerships
REGULATED PRESS RELEASE

published on 09/15/2025 at 07:00, 9 months 6 days ago

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
Biophytis secures public funding in Brazil for Obesity Phase 2 trial and signs agreements with leading local clinical partners, strengthening its OBA Phase 2 program and obtaining non-dilutive funding support through EMBRAPII

Biophytis Public Funding EMBRAPII Obesity Phase 2 Trial Clinical Partners
BRIEF

published on 09/11/2025 at 07:05, 9 months 10 days ago

Biophytis Announces Phase 3 Sarcopenia Trial for BIO101 in Europe and Asia

Age-related Diseases BIO101 Sarcopenia Clinical Trial Biophytis Strategy Asia And Europe
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 9 months 10 days ago

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia
Biophytis announces Phase 3 Sarcopenia Trial Strategy with BIO101 targeting age-related sarcopenia in Europe and Asia, aiming to address a significant unmet medical need and commercial market

Biophytis Clinical Trial Sarcopenia Phase 3 BIO101
BRIEF

published on 09/03/2025 at 07:05, 9 months 18 days ago

Biophytis Advances Obesity Treatment with EMA Approval

Biophytis Obesity Treatment Clinical Trial BIO101 EMA Authorization
REGULATED PRESS RELEASE

published on 09/03/2025 at 07:00, 9 months 18 days ago

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity
Biophytis obtains EMA authorization to launch Phase 2 clinical trial of BIO101 in obesity, marking a significant regulatory milestone in Europe

Biophytis Phase 2 Clinical Trial Obesity EMA Authorization Regulatory Milestone
BRIEF

published on 09/01/2025 at 07:05, 9 months 20 days ago

Biophytis Announces Phase 2 Obesity Trial with BIO101

Biophytis Phase 2 Trial BIO101 Obesity Muscle Wasting
REGULATED PRESS RELEASE

published on 09/01/2025 at 07:00, 9 months 20 days ago

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil
Biophytis reveals Phase 2 Obesity Trial Strategy for BIO101 in Europe and Brazil, targeting muscle wasting in obese patients. Expanding therapeutic horizons and commercial prospects

Biophytis Phase 2 BIO101 Muscle Wasting Obesity Trial
PRESS RELEASE

published on 09/01/2025 at 06:59, 9 months 20 days ago

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil
Biophytis unveils Phase 2 Obesity Trial Strategy for BIO101 in Europe and Brazil, targeting muscle wasting associated with obesity. The new program broadens potential and value-creation opportunities globally

Biophytis Phase 2 BIO101 Muscle Wasting Obesity Trial
BRIEF

published on 08/28/2025 at 07:05, 9 months 24 days ago

Biophytis Gains Regulatory Approval for Phase 3 Sarcopenia Trial

Biophytis Regulatory Approval Clinical Trial Sarcopenia Phase 3

Accesswire

Published on 06/20/2026 at 01:00, 1 day 15 hours ago

Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 16 hours ago

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 2 days 12 hours ago

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 15 hours ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 15 hours ago

Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting

View all ACCESSWIRE

EQS Group

Published on 06/20/2026 at 21:25, 19 hours 34 minutes ago

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 1 day 10 hours ago

Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 20 hours ago

2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 19:01, 1 day 21 hours ago

Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 18:29, 1 day 22 hours ago

Designated Person Notification

Les Echos

Published on 06/19/2026 at 19:33, 1 day 21 hours ago

Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day 21 hours ago

Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/18/2026 at 18:00, 2 days 22 hours ago

Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 2 days 23 hours ago

EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 2 days 23 hours ago

Statement of transactions in own shares from June 8, 2026 to June 12, 2026

View all LES ECHOS COMFI WIRE